Idorsia Ltd. · SIX:IDIA
Idorsia — Fact Sheet (October 2023)
7 slides from Idorsia's fact sheet, October 2023
Slide 1: Idorsia Company Profile
Idorsia Company Profile Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development, and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. We
Slide 2: Share Information and Company Strategy
Share Information Company Strategy Idorsia was incorporated in March 2017 We will develop Idorsia into a leading Bring Idorsia to sustainable profitability and listed on the SIX Swiss Exchange (ticker biopharmaceutical company, with a strong We are building Idorsia with a long-term symbol: IDIA) in
Slide 3: Innovation portfolio
Innovation portfolio Product / compound Mechanism of action Therapeutic area Status QUVIVIQ™ Dual orexin receptor antagonist Insomnia Commercially available in the US, Germany, Italy, and (daridorexant) Switzerland; approved in the EU, UK, and Canada; Filing in Japan expected H2 2023; Phase 2 in ped
Slide 4: Partnerships
Partnerships Halozyme Syneos Health In 2019, Idorsia entered into a global agreement with Halozyme to In 2020, Idorsia and Syneos Health entered into an innovative develop a novel drug-device product combining selatogrel – Idorsia’s commercial partnership to build the salesforce for the US launch po
Slide 5: Company milestones
Company milestones 2023 2022 June QUVIVIQ (daridorexant) launched in December NDA for aprocitentan submitted May Europe’s first dual orexin receptor Switzerland to the US FDA for the treatment of patients antagonist – QUVIVIQ (daridorexant) – with difficult-to-control hypertension granted approval t
Slide 6: Company milestones 2017-2021
2021 2020 2019 December Idorsia to further characterize July Establishment of Idorsia November Collaboration Agreement with lucerastat for Fabry disease by continuing Pharmaceuticals US Inc. to perform Halozyme for the development of a novel the open-label extension of the Phase 3 commercial operati
Slide 7: About Idorsia, disclaimer and contact
Idorsia is an independent biopharmaceutical company based on science and innovation. The company is specialized in the discovery, development, and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. It is headquartered in Allschwil/Basel,